Food Effect Clinical Trial
— MMMOfficial title:
Characterisation of Gastrointestinal Transit of Four New Developed Gel Matrix Tablets With Different Erosion Rates by Means of MMM Measurement Under Fasting and Fed Conditions
Verified date | November 2010 |
Source | AstraZeneca |
Contact | n/a |
Is FDA regulated | No |
Health authority | Germany: Ethics Commission |
Study type | Interventional |
The purpose of this study is to monitor the gastrointestinal transport of eroding gel matrix placebo tablets in healthy male volunteers under fasting and fed conditions. The method which is used is an imaging technique.
Status | Completed |
Enrollment | 5 |
Est. completion date | November 2010 |
Est. primary completion date | November 2010 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Male |
Age group | 18 Years to 55 Years |
Eligibility |
Inclusion Criteria: - Ethnic origin: Caucasian - Body-mass index (BMI): = 19 kg/m² and = 27 kg/m² - Good health - Written informed consent, after having been informed about benefits and potential risks of the trial Exclusion Criteria: - Diseases which could influence the gastric emptying and gastrointestinal transport - Diet which could influence the gastric emptying and gastrointestinal transport - Surgery in the gastrointestinal tract which may interfere with the safety and transport of test product - Ferromagnetic implants or any other magnetic disturbance, which can affect the Magnetic Marker Monitoring measurement - Regular medical treatments which could affect the gastric emptying and gastrointestinal transport |
Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science
Country | Name | City | State |
---|---|---|---|
Germany | Research Site | Berlin |
Lead Sponsor | Collaborator |
---|---|
AstraZeneca |
Germany,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The time from an administration of each of the placebo gel matrix tablets of each arm until Gastric Emptying Time (GET) | No | ||
Primary | The time from an administration of each of the placebo gel matrix tablets of each arm until Colon Arrival Time (CAT) | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04501640 -
A Study to Investigate the Effect of Food With Mirabegron in Healthy Chinese Participants
|
Phase 4 | |
Withdrawn |
NCT02560363 -
A Study to Compare the Pharmacokinetics of Different Formulations of AZD9977 and the Influence of Food in Healthy Male Subjects
|
Phase 1 | |
Completed |
NCT02017236 -
A Food Effect Phase I Study of the Volitinib in Healthy Subjects
|
Phase 1 | |
Completed |
NCT03150498 -
A Food Effects Study and Optional Multi Dose Study to Assess PK of BTD-001
|
Phase 1 | |
Completed |
NCT01686217 -
A Phase I Study to Compare 3 Different Strengths of an Extended Release Formulation of ASP015K to an Immediate Release Formulation of ASP015K
|
Phase 1 | |
Completed |
NCT01322464 -
Study to Assess Food Effect on Sativex Bioavailability
|
Phase 1 | |
Completed |
NCT03885778 -
A Food Effect Study of Besifovir in Healthy Subjects
|
Phase 4 | |
Completed |
NCT05690932 -
A Formulation Bridging and Food Effect Study of PBI-200 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT05187169 -
Food Effect of VS-6766 in Healthy Adult Subjects
|
Phase 1 | |
Completed |
NCT05217732 -
Study to Assess the Safety, Tolerability and Pharmacokinetics of ZX-7101A and the Food Effect in Healthy Volunteers
|
Phase 1 |